DIMA Biotechnology LLC accelerates cancer research through innovative membrane protein and monoclonal antibody discovery platforms. We specialize in producing full length, hard-to-express targets such as GPCRs, ion channels, and transporters et al. All our proteins are overexpressed in HEK293 cells to ensure high quality expression with correct PTMS. Our proprietary platforms include: – Synthetic Nanodisc, PeptiNanodisc, and Detergent-based systems: providing pure full length transmembrane proteins purified by affinity chromatography. – VLP (Virus Like Particles), MNP (Membrane Nano Particles), and Exosome-based systems—which present proteins in their native context but are not purified proteins. We offer over 500 Nanodisc products, with 300+ available in stock for next day delivery covering many GPCR and channel proteins. In antibody discovery, we provide both single B cell–derived rabbit mAbs and Nanobody development. We offer 5,000+ prevalidated recombinant mAb sequences targeting 500+ cancer relevant proteins, which are ready for out-licensing and testing. Additional IgG candidates can be screened within six weeks using proprietary B cell libraries. Our mammalian cell display platform supports antibody engineering services including humanization, affinity maturation, and functional screening. DIMA delivers integrated solutions from membrane protein production to antibody optimization to advance cancer research and therapeutic development.
Dakewe (Biosci & Exreprotein)
Dakewe group was founded in 1999 and is headquartered in Shenzhen, China. Our business involves in self-developed histology equipment and scientific research reagents. Dakewe group has more than 14 branches based both in China and overseas, including Beijing, Shanghai, Hong Kong, USA, Europe and India, and more. Meanwhile, Dakewe is consistently complementing the service and distribution network to provide quality products and service to customers all around the world. Dakewe products have been sold to more than 60 countries/regions and served more than 10000 users.
Cytiva
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more. | Diagnostic assays like the ones you’re developing are in demand. Set yourself up for success by choosing a supplier that delivers quality products for your entire workflow and offers specialized services and capabilities needed to commercialize your assays. Using a single supplier for multiple components, from membranes to magnetic beads, can streamline your development process and ultimately accelerate the commercialization of diagnostic assays and kits. Cytiva can help you speed up and scale up without staffing up! With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical knowledge and talent, a broad and deep portfolio, and exceptional service to support biotechs at every stage from discovery to delivery. Visit cytiva.com/diagnostics to learn more. | Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. | Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Cytosurge AG
Cytosurge is a biotechnology company that provides the world’s only technology that allows scientists to physically access, perturb, and profile the same living cell over time, enabling insights that snapshot methods cannot capture > FluidFM combines microfluidics and force microscopy to enable gentle interactions with cells; based on this unique technology, we empower scientists to read, write, and analyze life as it unfolds. Experience the revolution of Same-Cell Biology with FluidFM OMNIUM. The single-cell biopsy solution on the FluidFM OMNIUM platform provides a unique workflow for extraction of a part of the cytoplasm from individual living cells while preserving their viability. These cytoplasmic biopsies can be used for subsequent highly sensitive, low-input RNA-seq analysis to characterize single-cells multiple times throughout their lifetime. This enables temporal profiling to track how baseline states and treatments causally drive future behavior, delivering data that reveals mechanisms rather than just correlations. CellEDIT service: Vector-free, controlled genome engineering. Empowered by FluidFM, CellEDIT delivers precise doses without vectors, multiplex edits even in hard-to-transfect cells—without viral toxicity or electroporation. We provide unprecedented control to generate clean, reproducible, and physiologically relevant models. Finally obtain the edits you need, reliably. You name the edit, we edit it. BOOTH #617.
CUSABIO TECHNOLOGY LLC
CUSABIO Technology is a National High-Tech Enterprise with research, production, and sales in one. After 18 years of effort, CUSABIO has become a good partner to researchers worldwide. We are dedicated to providing 67,000+ validated antibodies, 12,000+ recombinant proteins, 660+ cytokines, and thousands of ELISA kits to global customers in the research fields of cancer, cell biology, immunology, neuroscience, epigenetics, etc. Our products can meet customers’ different demands in various scientific research fields.
Curia Global, Inc
Curia is a global Contract Development and Manufacturing Organization with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing to make treatments broadly accessible to patients. We offer services across Small Molecules, Generic APIs, and Biologics backed by deep scientific expertise and a robust global network of resources and capabilities. Our dedicated teams, combined with advanced technologies, enable us to be both flexible and scalable, accelerating the delivery of your product to patients. From curiosity to cure, we are your trusted ally, delivering every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com | Curia is a global CDMO with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing. Our Biologics services span discovery to clinical manufacturing, including clinical and commercial fill-finish services, for antibodies, recombinant proteins, mRNA therapeutics and many large molecule products. Curia’s expertise and agility deliver a best-in-class experience across discovery, drug substance and drug product development and manufacturing. From curiosity to cure, we are your trusted ally to accelerate life-changing therapeutics. To learn more, visit us at https://curiaglobal.com/biologics/
Curiosis
Curiosis Inc. is dedicated to developing, producing, and supplying innovative systems for cell-based analysis and lab automation. Our advanced solutions are designed to enhance the efficiency, precision, and scalability of cell-based research, helping scientists and medical professionals achieve better outcomes. We strive to establish ourselves as a leader in the bioindustry, focusing on delivering products that meet the evolving needs of both scientific and medical communities. By integrating cutting-edge technologies and fostering continuous innovation, we aim to make significant contributions to the advancement of biomedical research and the improvement of global healthcare outcomes.
CTCELLS
CTCELLS is an innovative cancer diagnostics and drug development company founded on the belief that effective cancer care requires solutions tailored to each individual. Powered by Circulating Tumor Cell (CTC) liquid biopsy, CTCELLS enables automated isolation of diverse CTC subtypes to better capture the full biological heterogeneity of cancer. To translate these insights into actionable research and clinical value, CTCELLS integrates its proprietary Continuous Centrifugal Microfluidics (CCM) technology for robust, automated CTC processing, lossless cell staining enabled by hydrogel-based HypICC to preserve cellular information for downstream analysis, and single-cell picking to support precise molecular profiling and functional characterization. By connecting cancer-specific cellular characteristics with the most suitable therapies, CTCELLS is committed to improving patient outcomes and accelerating the development of next-generation treatments, bringing new hope to patients facing difficult-to-treat cancers. | CTCELLS is an innovative biotechnology company striving for a total solution for cancer. With platform technologies in both therapeutics and diagnostics, the RACE platform is designed to deliver safer and more effective immunotherapies by optimizing the selection and administration of treatment based on a patient’s unique immunological profile. The TRACE Platform, on the other hand, is a cutting-edge liquid biopsy system that captures all types of Circulating Tumor Cells (CTCs). This allows for more precise diagnostics and treatment planning, targeting a range of cancer types. CTCELLS is committed to improving patient outcomes by integrating the latest in scientific research and technology into their products.
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that drive drug discovery and development in oncology and immuno-oncology. We provide a range of integrated solutions, which include preclinical research services, translational platforms, and clinical trial support. Our offer includes the world’s largest commercially available patient-derived xenograft (PDX) collection and over 600 tumor organoid models using Hubrecht Organoid Technology, covering 22 cancer indications. Our expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in vitro, ex vivo, and in silico methods, along with advanced laboratory services that span the entire drug development timeline. Additionally, we maintain an extensive biobank of liquid and human biospecimens, complete with clinical histories. Operating from 11 facilities in the US, Europe, and APAC—including laboratories accredited by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO)—we ensure the highest standards of quality and reliability in our research environments. For more information, please visit www.crownbio.com. | Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. Known for their high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Additionally, further services available in the areas of high content imaging and a 3D Ex Vivo Patient Tissue Platform, provide greater insights into complex disease pathophysiology. A range of biomarker analysis and applied genomics services are also available to optimize therapeutic benefit. Crown Bioscience helps to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe, and Asia. Find out more: www.crownbio.com
Creative Biomart Inc
Creative BioMart is a leading biotech company that provides innovative products and services to the scientific community worldwide. We specialize in developing and manufacturing high-quality recombinant proteins, and custom services for life science research, drug discovery, and diagnostic applications. We pride ourselves on our customer-centric approach, which ensures our customers receive exceptional service and support at every stage of their research project. Whether you need any help, our team is always available to help.